ERBB2 and breast cancer: Our yearly costs in patients with early HER2+ BC were lower than in the US study but were averaged for the duration of follow-up, as opposed to a more treatment-intense first year alone (as in the US study); further, both the patient population and health care system differ greatly in Canada compared to the US.